Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sumatriptan

FDA-approved product (spray, nasal), marketed as Imitrex, Sumatriptan, Tosymra and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sumatriptan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin (5ht1) agonists
FDA pharmacologic class
Serotonin-1b and Serotonin-1d Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sumatriptan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sumatriptan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Trial Designs for Evaluating Migraine Treatment

    NCT06617832 · start 2024-11-13

    Registered record
    Registry ID
    NCT06617832
    Conditions
    Migraine With Aura; Migraine Without Aura; Headache, Migraine
    Interventions
    Active drug for acute migraine treatment; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-11-13
    Completion
    2028-09
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine With Aura; Migraine Without Aura; Headache, Migraine
    InterventionActive drug for acute migraine treatment; Placebo Oral Tablet
    PhaseNot applicable
    Registry statusRecruiting

  • Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

    NCT06503848 · start 2024-01-25

    Registered record
    Registry ID
    NCT06503848
    Conditions
    Migraine Disorders
    Interventions
    Sumatriptan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-01-25
    Completion
    2024-12
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionSumatriptan
    PhaseNot recorded
    Registry statusUnknown

  • Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women

    NCT05854992 · start 2022-07-05

    Registered record
    Registry ID
    NCT05854992
    Conditions
    Migraine; Cardiovascular Diseases; Pregnancy
    Interventions
    Acute migraine treatment with any prescribed triptans; Standard of care management of acute migraine without triptans
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-07-05
    Completion
    2024-11-01
    Enrolment
    68,419

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Cardiovascular Diseases; Pregnancy
    InterventionAcute migraine treatment with any prescribed triptans; Standard of care management of acute migraine without triptans
    PhaseNot recorded
    Registry statusCompleted

  • i-NEED: NEw migrainE Drugs Database

    NCT07103694 · start 2022-03-24

    Registered record
    Registry ID
    NCT07103694
    Conditions
    Episodic Migraine; Chronic Migraine; Medication Overuse Headache
    Interventions
    anti-CGRP monoclonal antibodies; gepants; combination of sumatriptan and naproxen; ditan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-03-24
    Completion
    2026-12-31
    Enrolment
    2,641

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpisodic Migraine; Chronic Migraine; Medication Overuse Headache
    Interventionanti-CGRP monoclonal antibodies; gepants; combination of sumatriptan and naproxen; ditan
    PhaseNot recorded
    Registry statusRecruiting

  • Sumatriptan and Glucose

    NCT04690270 · start 2021-01-04

    Registered record
    Registry ID
    NCT04690270
    Conditions
    Overweight
    Interventions
    Sumatriptan 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2021-01-04
    Completion
    2021-06-25
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOverweight
    InterventionSumatriptan 100 mg
    PhaseEarly phase 1
    Registry statusUnknown

  • A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.

    NCT04355845 · start 2020-06-15

    Registered record
    Registry ID
    NCT04355845
    Conditions
    Healthy Volunteers
    Interventions
    Sumatriptan; PF-06651600
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-06-15
    Completion
    2020-08-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionSumatriptan; PF-06651600
    PhasePhase 1
    Registry statusCompleted

  • Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache

    NCT04257851 · start 2020-02-15

    Registered record
    Registry ID
    NCT04257851
    Conditions
    Post-Dural Puncture Headache
    Interventions
    Theophylline Anhydrous Oral Tablet; Sumatriptan Succinate Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-02-15
    Completion
    2021-05-15
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Dural Puncture Headache
    InterventionTheophylline Anhydrous Oral Tablet; Sumatriptan Succinate Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

    NCT03877718 · start 2019-02-01

    Registered record
    Registry ID
    NCT03877718
    Conditions
    Migraine; Pain; Nausea; Vomiting; Aura
    Interventions
    Arm 1: CL-H1T; Arm 2: CL-H1T; Arm 3: Sumatriptan Succinate 100 mg capsule; Arm 4: Promethazine HCl 18.75 mg; Arm 5: Promethazine HCl 37.5 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-02-01
    Completion
    2019-08-27
    Enrolment
    475

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Pain; Nausea; Vomiting +1 more
    InterventionArm 1: CL-H1T; Arm 2: CL-H1T; Arm 3: Sumatriptan Succinate 100 mg capsule; Arm 4: Promethazine HCl 18.75 mg +2 more
    PhasePhase 2
    Registry statusCompleted

  • PACAP38 Induced Headache and Rosacea-like Symptoms in Patients With Rosacea

    NCT03878784 · start 2018-11-12

    Registered record
    Registry ID
    NCT03878784
    Conditions
    Rosacea
    Interventions
    Imigran; Isotonic Saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-11-12
    Completion
    2019-12-19
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRosacea
    InterventionImigran; Isotonic Saline
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting

  • PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

    NCT03881644 · start 2018-07-17

    Registered record
    Registry ID
    NCT03881644
    Conditions
    Migraine Without Aura
    Interventions
    Imigran; Isotonic Saline; Pituitary adenylate cyclase-activating peptide-38
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-07-17
    Completion
    2019-12-07
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Without Aura
    InterventionImigran; Isotonic Saline; Pituitary adenylate cyclase-activating peptide-38
    PhaseNot applicable
    Registry statusCompleted

  • The Effect of Sumatriptan and Placebo on CGRP Induced Headache

    NCT03542357 · start 2018-02-15

    Registered record
    Registry ID
    NCT03542357
    Conditions
    Migraine
    Interventions
    Calcitonin Gene Related Peptide; Sumatriptan 50 mg; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-02-15
    Completion
    2018-09-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionCalcitonin Gene Related Peptide; Sumatriptan 50 mg; Placebo Oral Tablet
    PhaseNot applicable
    Registry statusCompleted

  • The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache

    NCT03422796 · start 2017-11-01

    Registered record
    Registry ID
    NCT03422796
    Conditions
    Migraine
    Interventions
    Cilostazol 200mg; SUMAtriptan 6 MG/ML; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-11-01
    Completion
    2018-09-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionCilostazol 200mg; SUMAtriptan 6 MG/ML; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants

    NCT03310411 · start 2017-10-17

    Registered record
    Registry ID
    NCT03310411
    Conditions
    Healthy
    Interventions
    Lasmiditan; Sumatriptan; Placebo for Lasmiditan; Placebo for Sumatriptan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-17
    Completion
    2017-12-23
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLasmiditan; Sumatriptan; Placebo for Lasmiditan; Placebo for Sumatriptan
    PhasePhase 1
    Registry statusCompleted

  • Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers

    NCT03156920 · start 2017-05-23

    Registered record
    Registry ID
    NCT03156920
    Conditions
    Migraine
    Interventions
    Placebo; Sumatriptan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-05-23
    Completion
    2017-10-18
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionPlacebo; Sumatriptan
    PhaseNot applicable
    Registry statusCompleted